Company Profile
Beam Therapeutics Stock Price, News & Analysis
- Ticker:
- BEAM
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
27.25 USD (+0.66%)
Close
Last updated: August 6, 2026
2.98B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, BEAM closed up 0.66% at $27.25. No new same-company headline was identified in the current news window.
Company overview
Base Editing
Beam Therapeutics develops precision genetic medicines using base editing, which can change individual DNA bases without creating double-strand breaks. The company integrates editing, delivery and manufacturing capabilities.
BEAM-302
BEAM-302 is an in vivo liver-editing candidate for alpha-1 antitrypsin deficiency and is moving into a global pivotal cohort.
BEAM-301
BEAM-301 is an in vivo base-editing therapy for glycogen storage disease type Ia that has entered clinical evaluation.
BEAM-304
BEAM-304 is a liver-directed base-editing candidate for phenylketonuria and is preparing for an IND submission.
Sickle Cell Disease
Risto-cel is an ex vivo base-edited hematopoietic stem-cell therapy for sickle cell disease and is approaching a potential U.S. regulatory submission.
Future catalysts
Initiation of a global pivotal cohort for BEAM-302 in the second half of 2026.
IND submission for BEAM-304 during 2026.
Additional BEAM-301 clinical data during 2026.
BLA submission for risto-cel as early as year-end 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference
Source: Beam Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Beam Therapeutics (BEAM)?
Beam Therapeutics (BEAM) most recently closed at 27.25 USD, a +0.66% move versus the previous session.
What is the market cap of Beam Therapeutics (BEAM)?
Beam Therapeutics currently has a market capitalization of 2.98B USD on BioPharmSignal.
What does Beam Therapeutics do?
Base Editing Beam Therapeutics develops precision genetic medicines using base editing, which can change individual DNA bases without creating double-strand breaks. The company integrates editing, delivery and manufacturing capabilities. BEAM-302 BEAM-302 is an in vivo liver-editing candidate for alpha-1 antitrypsin deficiency and is moving into a global...
On which exchange is BEAM stock listed?
Beam Therapeutics (BEAM) is associated with NASDAQ, United States, Biopharma.
What is BEAM-302?
Initiation of a global pivotal cohort for BEAM-302 in the second half of 2026.
Which conditions is Beam Therapeutics targeting with BEAM-302?
Beam Therapeutics is associated with genetic disease based on its company overview and current catalyst commentary.
How does Beam Therapeutics describe recent progress with BEAM-302?
Initiation of a global pivotal cohort for BEAM-302 in the second half of 2026.
What is BEAM-301?
BEAM-301 BEAM-301 is an in vivo base-editing therapy for glycogen storage disease type Ia that has entered clinical evaluation.